lncRNA discovery has immensely accelerated. It turns out that lncRNA expression is tightly controlled in a spatial, temporal, cell-type specific manner suggesting functional relevance. Given the vast number of lncRNAs in the genome, delineating the function of lncRNAs is a topic of great interest. Among various examples of lncRNA functions (splicing, translation, etc.) , it seems that lncRNAs exert their main functions by providing a kind of guidance mechanism for directing epigenetic changes to the chromatin structure (Figure 2 ). lncRNAs can modulate chromatin architecture by binding to complementary sequences of partially single-stranded chromosomal DNA or nascent transcripts. Upon this interaction, chromatinmodifying proteins such as trithorax or polycomb groups of proteins can be recruited to the site where epigenetic alterations such as DNA methylation, nucleosome position changes, and histone modifications will take place (Nahkuri and Paro, 2012) . This way, lncRNAs can function as adaptors that aid in linking specific chromatin loci with chromatin-remodeling complexes as well as transcription factors. In addition, they can bind to transcription factors as decoys (Rapicavoli et al., 2013) to regulate their interactions with DNA or to miRNAs and act as sponges so that a specific pool of miRNAs fail to bind to the target mRNAs, etc. lncRNAs are also emerging as important regulators of immune cell differentiation and activation in innate and adaptive immunity pathways (Fitzgerald and Caffrey, 2014) . As we improve our understanding of how lncRNAs function, it seems there will be exciting developments in the field of cancer diagnosis and therapeutics. A promising example is the overexpressed prostate cancer gene 3 (PCA3) lncRNA that may prove to be better than existing biomarkers for prostate cancer (Sartori and Chan, 2014) .
Significant effort has been focused on new discovery of lncRNAs and their expression profiles. Studies so far also provided functional evidence on the mechanism of lncRNA actions. Several lncRNAs whose functions are validated experimentally can be listed as XIST (X inactivespecific transcript), HOTAIR (HOX transcript antisense), and HULC (highly upregulated in cancer) (Volders et al., 2013) . Here we will try to summarize recent literature on exemplary lncRNAs based on a classification of their genomic positions.
Linear lncRNAs

Antisense lncRNAs (also known as natural antisense transcripts)
LncRNAs that reside on opposite strands of protein-coding genes are called NATs and named after the protein-coding gene with an "-AS" suffix according to the HUGO Gene Figure 2 . A-LncRNAs can bind to regions of ssDNA to form a DNA-RNA heteroduplexes, or to dsDNA to form triplexes (DNA-DNA-RNA). B-lncRNAs can be tethered to a chromatin through association with chromatinmodifying proteins and/or transcription factors. C-lncRNAs can act as RNA decoys (e.g., Lethe). D-lncRNAs can take roles in RNA splicing/translation (e.g., sno-lncRNAs). E-lncRNAs in the form of endogenous competitors can bind to microRNAs and alter their mRNA target interactions.
Nomenclature Committee. NATs can act in cis or in trans. A cis-NAT overlaps with its complementary gene, whereas a trans-NAT does not overlap with its complementary gene. CDKN2B-AS1 (also known as ANRIL, antisense ncRNA in the INK4 locus) is an example of a cis-acting lncRNA. Mouse and human fibroblast studies showed combined binding of polycomb proteins and ANRIL to lead to epigenetic silencing of the INK4 locus Yap et al., 2010) . BACE1-AS is another cis-acting lncRNA that is antisense to the BACE1 gene that codes the β-secretase-1 enzyme. The BACE1-AS increase in Alzheimer disease may contribute to the increased stability of BACE1 mRNA and protein, which is a crucial enzyme in Alzheimer disease pathophysiology (Faghihi et al., 2008) .
Trans-acting NATs (i.e. complementary to a nonoverlapping region in the genome) exist as well. Examples of trans-acting NAT will be discussed below.
Intergenic lncRNAs
A well-studied example of an intergenic lncRNA (lincRNA) is MALAT1 (metastasis-associated lung carcinoma transcript 1), which is ubiquitously expressed and localized to the nucleus in normal tissues, and it sequence is strongly conserved from zebrafish to humans. MALAT1 has been linked to alternative splicing and epigenetic regulation (Tripathi et al., 2010; Yang et al., 2011b) . MALAT1 was initially identified in nonsmall cell lung cancers as a prognostic marker of survival (Ji et al., 2003) . However, loss of MALAT1 did not affect alternative splicing or cell cycle progression, (Gutschner et al., 2013) ; instead, MALAT1-deficient cells were impaired in cell migration and defective in forming metastatic tumor nodules. Surprisingly, loss of function mouse models did not generate a significant phenotype (Zhang et al., 2013a) .
HOTAIR (HOX antisense intergenic RNA) itself is derived from mammalian the HOXC homeotic cluster and can regulate HOXD (on a different chromosome) expression. HOTAIR also operates in trans as part of a structural scaffold by bridging chromatin with chromatinmodifying proteins, especially with the polycomb repressive complexes (Nahkuri and Paro, 2012) . Owing to this function, HOTAIR overexpression in cancer leads to genome-wide changes in the chromatin-modifying complex binding sites. Interestingly, HOTAIR expression was recently reported to be inversely correlated with miR-141 expression in renal carcinoma cells (Chiyomaru et al., 2014) . In essence, HOTAIR promotes malignancy, including proliferation and invasion, whereas miR-141 functions as a tumor suppressor. This inverse correlation is due to direct binding of miR-141 to HOTAIR in a sequence specific manner, supressing HOTAIR expression and functions including proliferation and invasion. Moreover, HOTAIR is overexpressed in breast, colorectal, hepatocellular, gastrointestinal, and pancreatic carcinomas (Beckedorff et al., 2013a) . These findings are also important to question the interactions of noncoding RNAs and microRNAs, further complicating our current understanding of microRNAs and their targets.
XIST is another lncRNA that contributes to nuclear compartmentalization and propagation of H3K27 methylation on the inactivated X chromosome (Xi), from which Xist is transcribed to equalize gene expression between the sexes. H3K27 methylation is a common histone modification directing silencing. Interestingly, Xist-deficient mouse hematopoietic stem cells show aberrant maturation and age-dependent loss, leading to highly aggressive myeloproliferative neoplasm and myelodysplastic syndrome (Yildirim et al., 2013) . TSIX is another lncRNA that is transcribed from the opposite strand of Xist to repress Xist, leading to DNA methylation of the Xist promoter (Ohhata et al., 2011) . 2.1.3. Intronic lncRNAs lncRNAs that reside in introns of protein-coding genes are called intronic lncRNAs. Sequences encoded within introns appear to host an unexplored reservoir of novel, functional RNAs known as sno-lncRNAs and antisense intronic lncRNAs (St Laurent et al., 2012) . While the majority of lncRNAs are found within intergenic regions, these intronic lncRNAs [no 5′ cap and no 3′ poly(A) tail] originate from excised introns. Although it is generally accepted that most of the excised introns or intron fragments are degraded after splicing, this observation may not hold true for some that are longer than 200 nucleotides and that could accumulate to high levels in cells (Yang et al., 2011a ). It appears that these spliced intronic sequences that reside in the nucleus have important roles as they harbor functional noncoding regions. We already know that a large number of snoRNAs are encoded within such intronic regions (Filipowicz and Pogacic, 2002) . Recently it became clear that some intronic regions harboring 2 snoRNAs are processed from their ends by the snoRNP machinery after splicing, but the internal intronic sequences between snoRNAs are not removed, leading to the accumulation of lncRNAs with snoRNA ends (snolncRNAs). Such RNAs appear to be widely expressed in cells. An abundant class of sno-lncRNAs (15q11-q13) is found to be deleted in Prader-Willi syndrome, and these sno-lncRNAs are associated strongly with Fox family splicing regulators and alter patterns of splicing (Yin et al., 2012) . Given these roles, deregulated expression of host genes and therefore of spliced intronic regions that harbor snoRNAs may have consequential effects on gene regulation in many aspects in cancer cells.
sno-independent cases of antisense intronic lncRNAs exist as well. RASSF1A (Ras association domain family 1 isoform A) is a tumor-suppressor gene shown to control cell proliferation in several tumors. ANRASSF1 is an antisense intronic lncRNA that is transcribed from the opposite strand of the RASSF1 gene. Expression of RASSF1A and ANRASSF1 follows an opposite pattern in cancer cells. ANRASSF1 forms an RNA/DNA hybrid and recruits chromatin-modifying enzymes to the RASSF1A promoter, reducing the expression of RASSF1A and increasing cell proliferation (Beckedorff et al., 2013b) .
Upstream/enhancer RNAs
The discovery that enhancer regions upstream of coding genes are transcriptionally active themselves was an astonishing finding in terms of understanding genomic complexity. Moreover, transcription from enhancer regions seems to be evolutionarily conserved, suggesting vital roles. Convincing evidence for the function of enhancer region transcripts comes from knockdown of specific lncRNAs (Orom et al., 2010) . When specific lncRNAs are depleted, neighboring genes' expressions were also downregulated. Such effects of lncRNAs can also be classified as a positive cis action where lncRNA-mediated enhancerpromoter looping occurs. Interesting studies revealed that genome-wide upregulation of estrogen induced lncRNAs positioned at enhancer sites/estrogen receptor binding sites of estrogen-responsive genes (Hah et al., 2013; . Similarly, PRNCR1 and PCGEM1 are 2 lncRNAs that are required for the activation of androgen receptor in prostate cancer cells. These lncRNAs are overexpressed in many aggressive prostate cancers, aiding androgendependent cell proliferation (Yang et al., 2013) . Such enhancer-derived noncoding RNAs seem to enhance transcriptional potential of genes by creating a permissive chromatin structure and/or physically interacting with activator proteins. These findings provide insight into how enhancer sites may have an influence on the promoter and eventually on gene expression. Therefore, not surprisingly, deregulated expression of such RNAs may have significant consequences on gene expression patterns.
Noncoding competing endogenous RNAs
Noncoding competing endogenous RNAs (ceRNAs) are hypothesized to act as microRNA sponges (Salmena et al., 2011) . It is indeed plausible to assume coding and noncoding RNA targets to crosstalk through their ability to compete for miRNA binding sites. Experimental evidence comes from PTEN and its pseudogene, PTENP1. Several binding sites for miRNAs that target PTEN are also found in the 3'-UTR of PTENP1 mRNA. It turns out that the pseudogene PTENP1 can regulate PTEN and exert a growth-suppressive role by acting as a miRNA binding decoy (Poliseno et al., 2010) . Further examples support these findings. LncRNA HULC is one of the upregulated genes in hepatocellular carcinoma (Panzitt et al., 2007) . CREB (cAMP response element binding protein) is involved in the upregulation of HULC (Wang et al., 2010) . HULC may act as an endogenous 'sponge' , which downregulates miRNA-372. This, in turn, leads to increased levels of its target gene, which can then induce the phosphorylation and activation of CREB as part of an autoregulatory loop.
Another example is Lethe, a pseudogene lncRNA. Lethe is transcribed by NF-kB, a transcription factor important in inflammation. In turn, Lethe binds directly to NF-kB and inhibits NF-kB DNA binding activity. These findings suggest that Lethe functions as a decoy, possibly to control the strength of the inflammatory response by directly interacting with the transcription factor (Rapicavoli et al., 2013) . Another class of lncRNAs, circular RNAs (circRNAs, discussed below), can also be considered as ceRNAs as they also harbor miRNA binding sites.
Transcribed ultraconserved regions
Transcribed ultraconserved region (T-UCR) transcripts are a novel class of lncRNAs that are transcribed from regions of the genome that can be considered as ultraconserved regions (UCRs). These regions were discovered upon the completion of genome sequencing of different species. It turns out, interestingly, that approximately 500 regions, UCRs, were found to be conserved (100% identity with no insertions or deletions) between the orthologous regions of the human, rat, and mouse genomes. These regions are considered as mutational cold spots. Furthermore, significant underrepresentation of single-nucleotide polymorphisms (SNPs) within UCRs also confirms their evolutional and functional importance (Katzman et al., 2007; Yang et al., 2008) . These genomic elements are longer than 200 bp (range: 200-779 bp), generally map to fragile sites, and can be intergenic, intronic, exonic, partly exonic, and exon-containing. Given their enrichment in cancer-associated genomic instability sites, genome-wide profiling revealed that T-UCRs have distinct expression signatures in different cancers with prognostic correlation (Calin et al., 2007; Scaruffi, 2011) . Hypermethylation of T-UCR CpG islands has also been reported in colon cancer, breast cancer, lung cancer, melanomas, leukemias, and lymphomas (Lujambio et al., 2010) . While the high homology implies a conserved function, we are far from understanding the functions of T-UCRs. Based on current findings, there are certain functions attributed to T-UCRS, such as long-range enhancer activity, transcriptional regulation, splicing, and epigenetic regulation (Scaruffi, 2011) . Understanding the roles of T-UCRs within these and potentially other contexts could pave the way for a better understanding of normal and cancer-related regulatory mechanisms. 2.5. Circular RNAs circRNAs can form naturally occurring circular structures that attract much attention because of their ability to bind and sequester miRNAs to abolish the repression of target mRNAs. circRNAs form by head-to-tail circularization of exons with covalently joined ends (Memczak et al., 2013) or from lariat introns (Zhang et al., 2013b) . Recent studies have suggested interesting roles of these circRNAs in gene expression. One example is exonic CDR1as (antisense to cerebellar degeneration-related protein 1), also known as CIRS7. CDR1as is predominantly expressed in the brain and has more than 70 miRNA binding sites; thus, CDR1as was categorized as a miRNA sponge (Hansen et al., 2013) . CDR1as strongly suppresses miR-7 activity, resulting in increased levels of miR-7 targets. Testis-specific circRNA, sex-determining region Y (Sry), also serves as a miR-138 sponge, suggesting that the miRNA sponge effects achieved by circRNA formation may be a widely utilized system in cells (Hansen et al., 2013) . However, intronderived circRNAs are interestingly less likely to harbor miRNA binding sites; they accumulate in the nucleus and interact with RNA polymerase II (Zhang et al., 2013b) . Therefore, they may have transcriptional roles other than recruitment of miRNAs.
Small noncoding RNAs
piwiRNAs (piRNAs)
piRNAs are small RNAs of 24-32 nucleotides long that are Dicer-independent and generally bind to PIWI proteins (a subfamily of argonaute proteins). piRNAs and PIWI proteins are known for their protective role in genome stability maintenance in germ lines (Brennecke et al., 2007) . piRNAs are transcribed from regions that harbor expressed transposable elements. piRNAs and PIWI form complexes to recognize these transcripts and direct their cleavage. For a long time, piRNAs were considered to be germline-specific defense elements for transposable elements, especially when PIWI depletion led to increased transposable element activity (Siomi et al., 2011) . Surprisingly, PIWI is also expressed in somatic cells while nongermline-specific piRNAs have been described in genome rearrangement and epigenetic programming, with biological roles in stem-cell function, whole-body regeneration, memory, and possibly cancer (Ross et al., 2014) . Interestingly, PIWI proteins have been implicated in DNA methylation as well, pointing to a role in epigenetic regulation (Esteller, 2011) . In support of this, a piRNA was implicated in DNA methylation of an imprinted mouse locus (Watanabe et al., 2011) .
In addition to normal physiological roles, cancerrelated findings are also intriguing. For example, somatic LINE1 element-induced insertional mutagenesis has been described in various epithelial cancers . Such insertions tend to occur in commonly mutated cancer genes that may serve for tumorigenesisrelated events in transformed cells. Accordingly, PIWI increases in these situations may have a suppressive and protective role. Indeed, PIWI expression has been studied in various somatic cancers and was proposed as a potential biomarker. In other cases, PIWI overexpression (PIWIL2) leads to antiapoptotic signaling and cell proliferation (Esteller, 2011) . It is clear that further research is needed to delineate the PIWI expression deregulation in cancers and whether it has any causative or protective roles. PIWI proteins have also been implicated in stem-cell renewal mechanisms (Ross et al., 2014) .
Recently, mature piRNAs and PIWI proteins were detected in cancer cell mitochondria (Kwon et al., 2014) . Further experiments are going to be exciting for investigation of the role of the piRNA-PIWI pathway in mitochondria in connection with cancer and possibly altered metabolic pathways and/or oxidative stress conditions. 3.2. microRNAs miRNAs are small noncoding RNAs of 19-25 nucleotides long that inhibit the translation and/or stability of mRNAs by binding to 3'-UTRs. Based on the explosive number of studies in the literature, we know that miRNAs are involved in various different processes including cellcycle regulation, differentiation, inflammation, apoptosis, and migration, mainly by controlling gene expression. Regulatory roles of miRNAs have been shown in almost all signaling pathways; consequently, dysregulation of miRNAs has been implicated in the development of human diseases including cancer.
miRNA genes are distributed throughout the genome, either between protein-coding genes (intergenic) or in their introns (intragenic). Almost all of the miRNA genes are transcribed by RNA polymerase II (Pol II) , possessing a 5' cap and a 3' poly(A) tail (Cai et al., 2004) . Still, a small group of Alu repeat-associated miRNAs have been shown to be transcribed by RNA polymerase III (Pol III) (Borchert et al., 2006) . miRNA biogenesis is a multistep enzymatic process that starts in the nucleus and ends in the cytoplasm. First, Pol II transcribes the miRNA gene into pri-miRNA (primary miRNA). These are transcripts of several kilobases long, which are characterized by stem-loop structures harboring the mature miRNA. In the nucleus, pri-miRNAs are cotranscriptionally recognized by the Microprocessor complex (Gregory et al., 2004; . The main components of the Microprocessor complex, the Drosha/DGCR8 heterodimer crops the primiRNAs into pre-miRNAs (precursor miRNAs), which are long hairpin structures of 60-100 nucleotides . DGCR8 is an RNA binding protein that is responsible for pri-miRNA hairpin recognition, while Drosha is an RNase III enzyme cropping the pri-miRNA. Next, Exportin-5 and its partner Ran-GTP recognize premiRNAs from their ~2 nt 3' overhangs and transport them to the cytoplasm (Yi et al., 2003) . In the cytoplasm, another RNase III, Dicer, recognizes pre-miRNAs and cleaves them into ~22 nt long miRNA/miRNA* duplexes (Hutvagner et al., 2001; Lee et al., 2003) . When miRNA duplexes interact with argonaute (Ago) proteins, the RNA-induced silencing complex (RISC) is formed. RISC usually binds to the 3'-UTR of target mRNAs by recognizing specific sequences called "seed sequences" with partial complementarity. RISC binding to the 3'-UTR causes either cleavage or translational repression of the mRNAs. In addition to canonical miRNA 3'-UTR targeting, some discrepancies have been reported, such as miRNAs binding to 5'-UTR of the mRNA to increase target gene translation (Orom et al., 2008) . 3.2.1. miRNAs and cancer miRNAs have been implicated in cancer development and progression since their discovery. Currently, it is well known that miRNAs can be upregulated or downregulated in numerous cancers (Erson and Petty, 2008; Selcuklu et al., 2009) . When miRNAs are downregulating tumor suppressor genes, they function as oncogenes/oncomiRs. On the other hand, they are called tumor-suppressor miRNAs when they are targeting oncogenes. Important regulatory roles of miRNAs have been implicated to affect all 6 hallmark capabilities of cancer (Hanahan and Weinberg, 2011) including sustaining proliferative signaling, evading growth suppressors, activating invasion and metastasis, enabling replicative immortality, inducing angiogenesis, and resisting cell death. However, miRNAs are also implicated in 2 emerging hallmarks: deregulating cellular energetics and avoiding immune destruction.
Sustaining proliferative signaling and evading growth suppressors are 2 fundamental hallmarks of tumorigenesis. In normal cells, homeostasis is preserved by controlling both mitogenic growth signals and antiproliferative signals. When miRNA profiles are altered in cancer cells, cell cycle regulators that are targeted by those miRNAs are also deregulated. For instance, the let-7 family of miRNAs has been shown to inhibit the RAS oncogene (Johnson et al., 2005) . Loss of let-7 expression has been linked to increased expression of RAS and progression of acute myeloid leukemia (Garzon et al., 2008) and lymphocytic leukemia (Marton et al., 2008) . Evasion of apoptosis is another hallmark of cancer. MiRNAs are able to repress or induce apoptosis by targeting proapoptotic or antiapoptotic genes, respectively. MiR-21 is an oncomiR that is overexpressed in almost all human cancers (Kumarswamy et al., 2011; Li et al., 2012) . MiR-21 targets apoptotic genes such as PTEN (Meng et al., 2007) , and PDCD4 (Asangani et al., 2008) , thus preventing programmed cell death, apoptosis.
Besides interfering with apoptosis, cancer cells avoid senescence and acquire a limitless replicative potential either by homologous recombination events at telomeres (Bailey et al., 2004) or by abnormal telomerase enzyme activation (Davison, 2007) . The role of miRNAs in this scenario was revealed after expression levels of miR-138 were associated with telomerase deregulation (Mitomo et al., 2008) . According to this study, miR-138 inhibits the human telomerase reverse transcriptase (hTERT) gene, and thus loss of miR-138 leads to increased hTERT in thyroid carcinomas. Another aspect of cancer cells is that they are capable of producing high amounts of proangiogenic factors to stimulate new blood vessel formation. A number of miRNAs such as miR-126, miR-378, and miR-296 have been named angioMiRs as a result of their contribution to angiogenesis (Wang and Olson, 2009) . Vascular endothelial growth factor (VEGF) levels, which are high in most tumors, are controlled at multiple levels. In zebrafish, miR-126 was found to repress negative regulators of the VEGF pathway, hence regulating angiogenesis and vascular integrity (Fish et al., 2008) .
Tumor invasion and metastasis is the leading cause of morbidity and mortality in human cancers. A series of complicated events including cellular detachment, microenvironmental motility, and spread to distant organs is orchestrated by various proteins (Chambers et al., 2002) . Involvement of miRNAs has been shown in various studies showing miRNA's effects on invasion and metastasis events (Baranwal and Alahari, 2010) . For instance, overexpression of miR-10b has been shown in metastatic breast cancer cases (Ma et al., 2007) . In this case, increased expression of miR-10b suppresses HOXD10 (homeobox D10) levels, which leads to increased RHOC (Ras homolog gene family, member C) levels, hence enhancing cells invasive and metastatic abilities.
Hallmarks of cancer have been evolving as the accumulating scientific data indicates the importance of cellular processes in cancer such as cellular energetics and avoidance of immune destruction. As with the previous 6 hallmarks, these newly emerging ones are also complicated with miRNA regulations. Evasion of immune surveillance by numerous strategies has been shown to be an ability of cancer (Curtale and Citarella, 2013) . For example, miR-155 has been shown to an important regulator of immune system function (Rodriguez et al., 2007) . MiR-155 regulates cytokines, chemokines, and transcription factors, which are necessary for normal immune function (Rodriguez et al., 2007) . miRNA regulation during immune responses in cancer is also of great interest (Pedersen and David, 2008) . For instance B7-H3, a surface immune-modulatory protein, inhibits natural killer cells and T cells. In normal tissues, expression of miR-29 decreases B7-H3 protein levels (Xu et al., 2009 ). However, miR-29 is downregulated in solid tumors such as sarcomas and neuroblastomas, such that B7-H3 protein levels are increased. The correlation between low miR-29 levels and B7-H3 expression has implications in immune system evasion of solid tumors.
Finally, cancer cell metabolism has gained attention with another cancer hallmark in recent years. As the existence of a metabolic switch in cancer cells is known, involvement of microRNAs has also been investigated. For example, miR-378 has been implicated in a metabolic shift in breast cancer cells by inhibiting expression of ERRγ (estrogen-related receptor γ) and GABPA (GA-binding protein α), thus causing reduction in TCA cycle gene expression and oxygen consumption leading to cellular proliferation (Eichner et al., 2010) .
As exemplified in all hallmarks of cancer, regulatory roles of miRNAs in cancer development and progression are substantial. Therefore, therapeutics strategies regarding inhibition or mimicking miRNAs are being investigated for treatment of human diseases including cancer (Ling et al., 2013; Nana-Sinkam and Croce, 2013) . The first cancertargeted miRNA drug, MRX34, is a liposome based miR-34 mimic that entered phase I clinical trials for hepatocellular carcinoma treatment (Bader, 2012; Bouchie, 2013) . Mir-34 has been shown to be a tumor-suppressor miRNA as it regulates multiple oncogenes such as BCL2, cyclin D1, and MYC, which are involved in the regulation of the cell cycle, proliferation, antiapoptosis, metastasis, and chemoresistance (Bader, 2012) . Mir-34 is downregulated in hepatocellular carcinomas; hopefully this replacement strategy will display potential therapeutic applications for miRNAs.
Taken together, additional research on novel miRNAs and their targets will enhance our knowledge of the roles of these regulators and hopefully these findings will speed the development of diagnostic and therapeutic applications for cancer. It is also worth noting that mRNAs can evade miRNA binding by alternative polyadenylation at 3'-UTRs (Sandberg et al., 2008; Akman and Erson-Bensan, 2014) . There is increasing evidence that some oncogenes may switch to shorter 3'-UTRs to avoid microRNA regulation in cancer cells (Mayr and Bartel, 2009; Akman et al., 2012) .
snoRNAs/scaRNAs
Small nucleolar RNAs (snoRNAs) and small Cajal body-specific RNAs (scaRNAs) are noncoding RNAs involved in the maturation of other RNA molecules. Small nucleolar RNAs (snoRNAs) are a class of small RNA molecules (60-300 bp) that are components of small nucleolar ribonucleoproteins (snoRNPs) to modify rRNA precursors during their maturation for ribosome assembly. These posttranscriptional modifications are either 2′-O-methylation by the C/D box snoRNAs or pseudouridylation by the H/ACA box snoRNAs in the nucleolus where ribosomes are formed. Several hundred snoRNAs have been mapped to intronic regions where they are processed by exonucleolytic trimming (Zhang et al., 2013b) .
It is clear that cells must coordinate ribosomal biogenesis with other cellular processes including cell proliferation. Not surprisingly, hyperactive ribosomal biogenesis has been implicated as a feature of cancer cells (Ruggero and Pandolfi, 2003) . Initial studies also suggested a potentially direct link between snoRNAs and cancer. For example, h5sn2, a H/ACA box snoRNA, was found to be significantly downregulated in human meningiomas compared with normal brain tissues (Chang et al., 2002) . Later, several studies addressed the significance of genomic instability regions that harbor snoRNA genes in various cancer types (Mannoor et al., 2012) . Furthermore, deregulated expression of snoRNAs along with small nucleolar ribonucleoprotein, fibrillarin, in murine and human breast cancer appears to be critical for tumorigenicity both in vitro and in vivo (Su et al., 2014) .
On the other hand, scaRNAs can modify snRNAs that mediate mRNA splicing. Deregulated expression of both snoRNAs and scaRNAs has been documented in various cancer types (Ronchetti et al., 2013; Lawrie et al., 2014) . Altered sno/scaRNAs expression and its consequences in terms of disease pathology are of future interest.
Endogenous small interfering RNAs (endo-siRNAs)
Initially, nematodes and Drosophila were demonstrated to have a well-defined endo-siRNA pathway. Deepsequencing small RNA analysis helped the discovery of mammalian/human endo-siRNAs that are ssRNAs of 20 nucleotides long that originate from endogenous dsRNAs such as antisense transcripts (cis-or trans-NATs), transposable elements, and hairpin RNA transcripts to repress either transposable elements or endogenous mRNAs .
Interestingly, a subset of differentially expressed endosiRNAs that directly regulate LINE-1 expression is depleted in human breast cancer cells compared to normal breast cells. These endo-siRNAs seem to regulate endogenous LINE-1 expression through increased DNA methylation of the LINE-1 5'-UTR promoter . Global mechanisms to regulate production of such endo-siRNAs and consequences of deregulated production of endosiRNAs remain to be investigated in cancer cells.
rasiRNAs (repeat-associated small interfering RNAs)
rasiRNAs have been identified in plants, fission yeast, Drosophila, and zebrafish. In mammals, rasiRNAs have not been specifically described. Hence a link between cancer and rasiRNAs has not been established yet. RasiRNAs are thought to have roles in gene silencing of repetitive sequence elements and transposable elements. RasiRNAs are most abundant in testes and early embryos, where regulation of transposon activity is critical and chromatin modeling occurs (Aravin et al., 2003) .
Conclusion
With the advancements of sequencing and high throughput analyses, we now better appreciate the significance of the noncoding part of our genome. The long undervalued noncoding transcripts are indeed quite abundant in cells performing various functions. Not only these functions but also how they interact with other noncoding RNAs, coding RNAs, and DNA is interesting to observe. These intertwined relationships will definitely provide a better understanding of the complexities of our cells. A better perspective on these normal events will then help us improve our knowledge on disease states, mainly cancer, where genomic instability and deregulated expression of genes is common. Hence, noncoding RNAs carry the potential for diagnostic and/or therapy strategies once their gene structures, expression profiles, and specific functions are better delineated. miRNAs are already considered as valuable biomarkers in certain tissue types/cancer types given their specific expression profiles in normal and cancer cells. Based on current evidence, at least some noncoding RNAs appear to have significant functions during gene expression, development, and differentiation. Consequently, their deregulation is highly associated with disease states. For example, there are clinical trials pursuing the use of noncoding RNAs in determining the predisposition to specific cancers. For the future, noncoding RNAs will not only be considered as biomarkers but also as targets for therapy. Such therapy approaches may utilize RNAi, aptamers, ribozymes, and small molecule drugs to target deregulated noncoding RNAs. It appears these and other novel approaches will be of great interest not only for cancer but other diseases such as cardiovascular and neurological diseases. Hopefully a comprehensive understanding of the genome and transcriptome will be the key to advances in such applications.
